Parkinson's disease and related neurodegenerative synucleinopathies linked to progressive accumulations of synuclein aggregates in brain

Parkinsonism & Related Disorders
John Q Trojanowski, V M.-Y. Lee

Abstract

Parkinson's disease (PD) is the most common neurodegenerative movement disorder and the classic clinical-neuropathological features of PD have been well established, including many aspects of the morphology and distribution the filamentous hallmark intraneuronal inclusions of PD known as Lewy bodies (LBs). Nonetheless, the mechanisms underlying brain degeneration in PD are unknown, while only partially effective symptomatic treatments for PD are available, and there are no known therepeutic interventions that are able to prevent PD or block or retard the progression of this relentless disorder. However, dramatic new insights into pathobiology of PD have emerged recently with recognition that alpha-synuclein abnormalities play a role in the onset and/or progression of PD. Moreover, continuing advances in this new research arena provide fresh research opportunities to advance understanding of PD, and these novel breakthroughs will accelerate discovery of more effective therapies for PD.

References

Jan 1, 1996·Journal of Neuropathology and Experimental Neurology·W SamuelL A Hansen
Aug 1, 1997·Nature Genetics·N Heintz, H Zoghbi
Apr 18, 1998·Neuroscience Letters·K WakabayashiH Takahashi
May 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·M G SpillantiniM Goedert
Jul 14, 1998·Nature Medicine·E MezeyM J Brownstein
Oct 8, 1998·The New England Journal of Medicine·A E Lang, A M Lozano
Nov 13, 1998·Current Opinion in Neurobiology·M GoedertS W Davies
Mar 27, 1999·The Journal of Biological Chemistry·L NarhiM Citron
Oct 6, 1999·Current Opinion in Neurobiology·J P Julien
Oct 9, 1999·The American Journal of Pathology·D W DicksonS H Yen
Dec 22, 1999·Journal of Neuropathology and Experimental Neurology·K L NewellB T Hyman

❮ Previous
Next ❯

Citations

Sep 5, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Katrina Gwinn-Hardy
Jul 16, 2008·Acta Neuropathologica·Thomas G BeachCharles H Adler
Dec 10, 2002·Neurobiology of Aging·Virginia M-Y Lee
Sep 23, 2011·Journal of Neuropathology and Experimental Neurology·Kunikazu TanjiKoichi Wakabayashi
Nov 10, 2001·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·L LonghiT K McIntosh
Mar 30, 2010·Neuropathology and Applied Neurobiology·I SuárezB Fernández
Mar 1, 2006·Molecular and Cellular Neurosciences·Dimitrios PapadopoulosRichard Reynolds
Aug 26, 2006·Current Opinion in Chemical Biology·O Sumner MakinLouise C Serpell
Jan 5, 2011·Neurobiology of Aging·Peter FilipcikMichal Novak
Jul 28, 2013·The American Journal of Pathology·David J IrwinJohn Q Trojanowski
Dec 24, 2004·Biochimica Et Biophysica Acta·Quan LiuGeorge Perry
Sep 29, 2011·Molecular and Cellular Neurosciences·Preeti J KhandelwalCharbel E-H Moussa
Jan 8, 2009·Biochemical and Biophysical Research Communications·Natasha DetersJürgen Götz
May 8, 2007·Biochimica Et Biophysica Acta·Ana Cuenda, Simon Rousseau
Mar 8, 2011·Brain Research·Alexander M HermanCharbel E-H Moussa
Dec 17, 2008·Progress in Retinal and Eye Research·Shunbin Xu
Nov 30, 2013·Pharmacology & Therapeutics·Frédéric Checler, Cristine Alves da Costa
Jul 21, 2009·Brain Research Bulletin·Natasa Bulat, Christian Widmann
Jan 24, 2009·Trends in Neurosciences·Tara L Spires-JonesBradley T Hyman
Jul 10, 2010·Neurobiology of Disease·Kun-Lin ChenChung Y Hsu
Oct 12, 2004·Gene·Max HolzerMichel Goedert
Aug 1, 2006·Neurobiology of Aging·Russell H Swerdlow
Jun 20, 2006·Biochemical and Biophysical Research Communications·David SingerRalf Hoffmann
Jul 25, 2006·FEBS Letters·Tetsuya TakahashiMasayasu Matsumoto
Apr 12, 2015·Experimental Neurology·Mingkuan Sun, Liam Chen
Sep 16, 2014·Experimental Gerontology·Chrisna SwartBen Loos
Jul 3, 2007·Neurobiology of Aging·Martina Wiedau-PazosDaniel H Geschwind
Jun 15, 2015·Progress in Neurobiology·Roy LardenoijeBart P F Rutten
Apr 18, 2009·Molecular Aspects of Medicine·Tobias JungTilman Grune
Dec 20, 2002·Journal of Geriatric Psychiatry and Neurology·Katrina Gwinn-Hardy, Amanda Adam Singleton
Mar 27, 2004·The Journal of Biological Chemistry·Jochen KluckenPamela J McLean
Apr 18, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Kelly Del Tredici, Heiko Braak
Aug 29, 2012·Acta Neuropathologica·Kelly Del Tredici, Heiko Braak
Oct 16, 2012·Journal of Neurology, Neurosurgery, and Psychiatry·Kelly Del Tredici, Heiko Braak
Dec 18, 2001·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Alessandro NegroLorenzo A Pinna
Jun 1, 2010·The Journal of Biological Chemistry·Ali Reza A LadiwalaPeter M Tessier
Aug 21, 2020·Learning & Memory·Jack T Rogers, Catherine M Cahill

❮ Previous
Next ❯

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alpha-Synuclein Aggregation (MDS)

Alpha-synucleins are small proteins that are believed to restrict the mobility of synpatic vesicles and inhibit neurotransmitter release. Aggregation of these proteins have been linked to several types of neurodegenerative diseases including dementia with Lewy bodies and Parkinson's disease. Here is the latest research on α-synuclein aggregation.